GORE EXCLUDER Conformable AAA Endoprosthesis
W. L. Gore and Associates, Inc. · Decision date Dec 5, 2025
What did the FDA approve?
FDA records P200030/S023 as a supplement to PMA P200030, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Dec 5, 2025.
FDA approval order statement
Approval for modification of the primary sewn tubular sleeve manufacturing process, a change to the primary sleeve attachment fiber, and a change to the proximal primary sleeve attachment pattern for the GORE EXCLUDER Conformable AAA Endoprosthesis.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 5, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P200030/S023
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore and Associates, Inc.
- Product code
- MIH
- Decision code
- APPR
- Decision date
- Dec 5, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT.
- Applicant
- W. L. Gore and Associates, Inc.
- Product code
- MIH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P200030/S022 · Related supplement
GORE EXCLUDER Conformable AAA Endoprosthesis (EXCC) 00733132650927; 00733132650934; 00733132650941; 00733132650958; 00
P200030/S023 received
Application receipt date recorded by FDA.
P200030/S023 · FDA decision
Real-Time Process
P200030/S024 · Related supplement
GORE EXCLUDER Conformable AAA Endoprosthesis
P200030/S025 · Related supplement
GORE EXCLUDER Conformable AAA Endoprosthesis
P200030/S026 · Related supplement
GORE EXCLUDER Conformable AAA Endoprosthesis
Timeline entries are records held by MedtechLedger for P200030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore and Associates, Inc. | PMA supplement | Aug 29, 2025 | FDA | |
GORE EXCLUDER Conformable AAA EndoprosthesisP200030/S024 | W. L. Gore and Associates, Inc. | PMA supplement | May 14, 2026 | FDA |
GORE EXCLUDER Conformable AAA EndoprosthesisP200030/S025 | W. L. Gore and Associates, Inc. | PMA supplement | Jul 8, 2026 | FDA |
GORE EXCLUDER Conformable AAA EndoprosthesisP200030/S026 | W. L. Gore and Associates, Inc. | PMA supplement | Jul 29, 2026 | FDA |
Explore the linked device profile
Other records with product code MIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RelayPro Thoracic Stent-Graft Delivery SystemP200045/S025 | Bolton Medical, Inc. | PMA supplement | Oct 28, 2026 | FDA |
| Cook, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Cook, Inc. | PMA supplement | Aug 4, 2026 | FDA | |
| Cook Medical Incorporated | PMA supplement | Aug 4, 2026 | FDA | |
| William Cook Europe Aps | PMA supplement | Aug 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore and Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 32360 N. N. Valley Pkwy., Phonix, AZ, 85085
Sources and methodology
- Original FDA record: P200030/S023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




